Adjusting ca19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center

HIGHLIGHTS

  • who: Zuowei Wu from the First Hospital, Peking University, China have published the research work: Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center, in the Journal: (JOURNAL) of May/16,/2017
  • what: The authors reviewed the patient data of the hospital and investigated the correlation between indicators and the overall survival (OS) as well as disease-free survival (DFS) of patients in different clinical stages. In compliance with the STROBE reporting checklist, the authors provide the following . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?